Lupin, Cost Plus Drug and COPD Foundation to expand access to medication for COPD patients

This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US

Global health challenges can be resolved using digital technology: Dr Alain Labrique

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

Lupin launches propranolol capsules to improve heart health in Canada

Propranolol LA is a generic equivalent of Inderal LA

European Commission approves Keytruda plus Trastuzumab and chemotherapy as first-line treatment for GEJ

KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population

CK Birla Hospital signs MoU Intuitive for robotic-assisted surgery

Hospital joins with Intuitive to install da Vinci systems to support enhanced healthcare delivery and patient outcomes across India

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

Bayer appoints Dr. Juergen Eckhardt as new Head of Pharmaceuticals Business Development & Licensing/Open Innovation

Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer

Lynparza plus abi/pred approved in Japan for treatment of prostate cancer

First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent

Intuitive and Max Healthcare to launch TPO Centre for robotic-assisted surgery

Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery